![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Interim Safety and Efficacy Results of the ABI-H0731 Phase 2a Program Exploring the Combination of ABI-H0731 with Nuc Therapy in Treatment-Naive and Treatment-Suppressed Chronic Hepatitis B Patients
|
|
|
Reported by Jules Levin
EASL 2019 April 10-14 Vienna
![0418191](../images/041919/041919-2/0418191.gif)
![0418192](../images/041919/041919-2/0418192.gif)
![0418193](../images/041919/041919-2/0418193.gif)
![0418194](../images/041919/041919-2/0418194.gif)
![0418195](../images/041919/041919-2/0418195.gif)
![0418196](../images/041919/041919-2/0418196.gif)
![0418197](../images/041919/041919-2/0418197.gif)
![0418198](../images/041919/041919-2/0418198.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|